Immunogenicity and Safety of 2 Doses of an Investigational Herpes Zoster Subunit Vaccine Administered 2, 6 or 12 Months Apart in Adults 50 Years and Older: Results of a Phase III, Randomized, Open-Label, Multicenter Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.